Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
64 hedge funds and large institutions have $342M invested in Avadel Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
23% more funds holding
Funds holding: 52 → 64 (+12)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
15% more capital invested
Capital invested by funds: $299M → $342M (+$43.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
71% less call options, than puts
Call options by funds: $1.07M | Put options by funds: $3.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$10.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$6.96M |
| 3 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$4.37M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$3.43M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$8.2M |
| 2 |
Millennium Management
New York
|
-$5.72M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$5.03M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$2.71M |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$2.21M |
AVDL Hedge Fund Activity: Q2 2014 in Review
64 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2014, worth a combined $342M — up 15% from $299M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AVDL positions and 8 closed out — a net gain of 12 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Clough Capital Partners, opening a new position worth an estimated $10.7M. The largest seller was Jennison Associates, cutting an estimated $8.2M.
- 64 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2014, up from 52 in Q1 2014.
- Funds reported $342M of Avadel Pharmaceuticals stock for Q2 2014, up 15% quarter-over-quarter.
- 20 funds opened new Avadel Pharmaceuticals positions in Q2 2014 and 8 closed out, a net change of +12 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2014 was Clough Capital Partners, an estimated $10.7M added.
- The largest Avadel Pharmaceuticals seller in Q2 2014 was Jennison Associates, an estimated $8.2M sold.
Based on aggregated 13F filings for Q2 2014.